Respiratory digital health company Adherium (ASX:ADR) has announced the appointment of a new CEO, Dr Paul Mastoridis.
Dr Mastoridis has more than 25 years of experience in the pharmaceutical industry, pioneering and leading digital solutions in asthma and COPD management.
Before joining Adherium, he was the Global Medical Head of Respiratory at Novartis.
In embracing the role of CEO at Adherium, Dr Mastoridis will contribute his expertise to bolster the Company’s commercialisation and market penetration strategy for its lead product, the Hailie® Smartinhaler system – with an immediate focus on the US.
Dr Mastoridis succeeds outgoing CEO, Rick Legleiter, who announced his resignation from Adherium last month.
Adherium independent non-executive chair, Lou Panaccio, said, “On behalf of my fellow directors, and the entire Adherium team, together with our valued shareholders and supporters, I welcome Dr Mastoridis to the position of CEO. In particular, we are celebrating his investment of highly specialised intellectual capital and valuable global networks to our growing business.
“I would also like to formally thank our outgoing CEO, Rick Legleiter, who has served our Company with focus, professionalism and integrity for the past 3 years – and who has committed to consulting to the Board and management team for up to 6 months to ensure a smooth transition on all operational fronts to his successor.”
Dr Mastoridis said, “This is a fantastic opportunity to revolutionise how we manage millions of asthma and COPD patients globally. Adherium is a business with a strong brand portfolio and is a respected leader in patient adherence, remote monitoring and data management solutions for patients, physicians and payers.
“Our Hailie Smartinhaler technology and patient management system will lead the industry by bringing these innovative devices to patients to help them reduce their exacerbations, hospitalisations, deaths and live better lives.”